文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

重症患者较高与较低蛋白质供给的效果:随机对照试验的更新系统评价与Meta分析及试验序贯分析

The effects of higher versus lower protein delivery in critically ill patients: an updated systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
PubMed 文献 · Crit Care · 2024-01-06
一句话结论一般重症患者较高蛋白质供给不影响临床结局,但合并急性肾损伤(AKI)患者较高蛋白质供给显著增加死亡率(RR 1.42,95%CI 1.11-1.82,需伤害人数7)。

该更新系统评价与Meta分析纳入23项随机对照试验(n=3303),比较成人重症患者较高与较低蛋白质供给(1.49±0.48 vs 0.92±0.30 g/kg/d),两组能量供给相似。较高蛋白质供给与总体死亡率无关(RR 0.99,95%CI 0.88-1.11;I²=0%;21项研究;低确定性),但在AKI亚组中显著增加死亡率(RR 1.42,95%CI 1.11-1.82;I²=0%;3项研究;试验序贯分析高确定性;需伤害人数7)。较高蛋白质供给还显著升高血清尿素(平均差2.31 mmol/L,95%CI 1.64-2.97;I²=0%;7项研究)。作者认为,一般重症患者较高蛋白质供给似乎不影响临床结局,但可能增加AKI患者死亡率;非AKI患者联合早期物理康复干预值得进一步研究。

要点

  • 在一般成人重症患者中,较高蛋白质供给(1.49±0.48 g/kg/d)与较低蛋白质供给(0.92±0.30 g/kg/d)相比,总体死亡率无显著差异(RR 0.99,95%CI 0.88-1.11;I²=0%;21项研究;低确定性)。
  • 在AKI患者亚组中,较高蛋白质供给显著增加死亡率(RR 1.42,95%CI 1.11-1.82;I²=0%;3项研究;试验序贯分析高确定性;需伤害人数7)。
  • 较高蛋白质供给显著升高血清尿素(平均差2.31 mmol/L,95%CI 1.64-2.97;I²=0%;7项研究)。
  • 在2项小型研究中,较高蛋白质供给联合早期物理康复对第90天自我报告的生活质量身体功能测量呈改善趋势(标准化平均差0.40,95%CI -0.04至0.84;I²=30%)。
  • 作者认为,一般重症患者较高蛋白质供给似乎不影响临床结局,但可能增加AKI患者死亡率;非AKI患者联合早期物理康复干预值得进一步研究。

适用人群与场景

  • 成人重症患者(纳入随机对照试验的人群);亚组分析包括AKI与非AKI/未知AKI患者。

处置流程与药物剂量

  • 较高蛋白质供给组蛋白质剂量为1.49±0.48 g/kg/d,较低蛋白质供给组为0.92±0.30 g/kg/d,两组能量供给相似。
  • 在AKI患者中,较高蛋白质供给可能增加死亡率(RR 1.42,95%CI 1.11-1.82;需伤害人数7),作者指出需进一步研究。

研究设计与关键结果

  • 研究类型:随机对照试验的更新系统评价与Meta分析及试验序贯分析;纳入23项随机对照试验,共3303例患者。
  • 较高蛋白质供给与总体死亡率无关(风险比[RR]:0.99,95%置信区间[CI] 0.88-1.11;I²=0%;21项研究;低确定性)。
  • 在AKI亚组中,较高蛋白质供给显著增加死亡率(RR 1.42,95%CI 1.11-1.82;I²=0%;3项研究;试验序贯分析证实为高确定性;需伤害人数为7)。
  • 较高蛋白质供给显著升高血清尿素(平均差2.31 mmol/L,95%CI 1.64-2.97;I²=0%;7项研究)。
  • 在2项小型研究中,较高蛋白质供给联合早期物理康复对第90天自我报告的生活质量身体功能测量呈改善趋势(标准化平均差0.40,95%CI -0.04至0.84;I²=30%)。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与Meta分析;总体死亡率为低确定性,AKI亚组死亡率经试验序贯分析为高确定性。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对于一般重症患者,较高蛋白质供给似乎不影响临床结局,但可能增加AKI患者的死亡率;在AKI患者中给予较高蛋白质需谨慎。
  • 作者指出,非AKI患者联合早期物理康复干预值得进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: A recent large multicentre trial found no difference in clinical outcomes but identified a possibility of increased mortality rates in patients with acute kidney injury (AKI) receiving higher protein. These alarming findings highlighted the urgent need to conduct an updated systematic review and meta-analysis to inform clinical practice.

METHODS: From personal files, citation searching, and three databases searched up to 29-5-2023, we included randomized controlled trials (RCTs) of adult critically ill patients that compared higher vs lower protein delivery with similar energy delivery between groups and reported clinical and/or patient-centred outcomes. We conducted random-effect meta-analyses and subsequently trial sequential analyses (TSA) to control for type-1 and type-2 errors. The main subgroup analysis investigated studies with and without combined early physical rehabilitation intervention. A subgroup analysis of AKI vs no/not known AKI was also conducted.

RESULTS: Twenty-three RCTs (n = 3303) with protein delivery of 1.49 ± 0.48 vs 0.92 ± 0.30 g/kg/d were included. Higher protein delivery was not associated with overall mortality (risk ratio [RR]: 0.99, 95% confidence interval [CI] 0.88-1.11; I2 = 0%; 21 studies; low certainty) and other clinical outcomes. In 2 small studies, higher protein combined with early physical rehabilitation showed a trend towards improved self-reported quality-of-life physical function measurements at day-90 (standardized mean difference 0.40, 95% CI - 0.04 to 0.84; I2 = 30%). In the AKI subgroup, higher protein delivery significantly increased mortality (RR 1.42, 95% CI 1.11-1.82; I2 = 0%; 3 studies; confirmed by TSA with high certainty, and the number needed to harm is 7). Higher protein delivery also significantly increased serum urea (mean difference 2.31 mmol/L, 95% CI 1.64-2.97; I2 = 0%; 7 studies).

CONCLUSION: Higher, compared with lower protein delivery, does not appear to affect clinical outcomes in general critically ill patients but may increase mortality rates in patients with AKI. Further investigation of the combined early physical rehabilitation intervention in non-AKI patients is warranted.

PROSPERO ID: CRD42023441059.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Lee ZY, Dresen E, Lew CCH, et al. The effects of higher versus lower protein delivery in critically ill patients: an updated systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Crit Care. 2024. PMID: 38184658. doi:10.1186/s13054-023-04783-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。